Market Chatter: Eli Lilly, Pfizer Among Drugmakers Eyeing a Spot in Chinese Commercial Health Insurance Catalog

MT Newswires Live
Aug 12

Eli Lilly (LLY), Pfizer (PFE), Novo Nordisk (NVO), and Biogen (BIIB) are among a number of Western pharmaceutical companies that have applied for their drugs and treatments to be included in China's new catalog of commercial health insurance, Bloomberg reported Tuesday.

The list includes Alzheimer's therapies from Eli Lilly, cancer treatments from Bristol-Myers Squibb (BMY), and an oral diabetes drug from Novo Nordisk. Other companies that featured in the list included Gilead Sciences (GILD), Johnson & Johnson (JNJ), and AstraZeneca (AZN), the report said.

A total of 121 drugs passed the preliminary evaluation, and a final decision is expected by October or November, the report added.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10